Neede, Netherlands

Wouter Kuit

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Morphochem Ag. Active years: 2005.


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Wouter Kuit: Innovator in Epothilone Synthesis

Introduction

Wouter Kuit is a notable inventor based in Neede, Netherlands. He has made significant contributions to the field of chemistry, particularly in the synthesis of epothilones, which are important compounds in cancer treatment.

Latest Patents

Wouter Kuit holds a patent titled "Epothilone Synthesis Building Blocks III and IV: Asymmetrically Substituted Acyloins and Acyloin Derivatives, Methods for Their Production and Methods for the Production of Epothilones B, D and Epothilone Derivatives." This invention focuses on novel acyloins and their derivatives, detailing methods for their production and their application in synthesizing epothilones and their derivatives. The patent highlights the innovative building blocks for epothilone synthesis and their production methods.

Career Highlights

Throughout his career, Wouter Kuit has worked with various companies, including Morphochem AG and Biosolum B.V. His work has contributed to advancements in pharmaceutical chemistry and the development of new therapeutic agents.

Collaborations

Wouter has collaborated with notable professionals in his field, including Ludger A. Wessjohann and Gunther Scheid. These collaborations have further enhanced his research and innovation in the synthesis of complex chemical compounds.

Conclusion

Wouter Kuit's contributions to the field of chemistry, particularly in epothilone synthesis, demonstrate his innovative spirit and dedication to advancing medical science. His work continues to impact the development of important therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…